TNF and Crohn disease: Notably, the FDA approved upadacitinib as the first oral treatment option for Crohn’s disease in patients with inadequate response or intolerance to tumor necrosis factor (TNF) blockers, highlighting its growing role in addressing unmet clinical needs across multiple inflammatory conditions (11, 12).